Pluristem Therapeutics Inc. (PSTI) announced that the independent Data Monitoring Committee of its global pivotal Phase III study for the treatment of critical limb ischemia or CLI issued its recommendation letter that the study is unlikely to meet the primary endpoint by the time of final analysis.
Meanwhile, DMC noted that PLX-PAD was well tolerated and no significant safety concerns were raised during the study.
Following the DMC's recommendation, Pluristem said it has decided to terminate the CLI study.
Pluristem CEO and President, Yaky Yanay, stated "We are deeply disappointed by the outcome of the CLI interim analysis,"
The company said it plans to focus on different therapeutic areas in its pipeline and expects three clinical readouts within the coming calendar year.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.